Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 Jul 4;24(13):11050.
doi: 10.3390/ijms241311050.

The CXCL13 Index as a Predictive Biomarker for Activity in Clinically Isolated Syndrome

Steven C Pike  1   2   3 , Francesca Gilli  1   2 , Andrew R Pachner  1
Affiliations

The CXCL13 Index as a Predictive Biomarker for Activity in Clinically Isolated Syndrome

Steven C Pike et al. Int J Mol Sci. .

Abstract

Multiple sclerosis (MS) is a clinically heterogenous disease. Currently, we cannot identify patients with more active disease who may potentially benefit from earlier interventions. Previous data from our lab identified the CXCL13 index (ICXCL13), a measure of intrathecal production of CXCL13, as a potential biomarker to predict future disease activity in MS patients two years after diagnosis. Patients with clinically isolated syndrome (CIS) or radiologically isolated syndrome (RIS) underwent a lumbar puncture and blood draw, and the ICXCL13 was determined. They were then followed for at least 5 years for MS activity. Patients with high ICXCL13 were more likely to convert to clinically definite MS (82.4%) compared to those with low ICXCL13 (10.0%). The data presented below demonstrate that this predictive ability holds true in CIS and RIS patients, and for at least five years compared to our initial two-year follow-up study. These data support the concept that ICXCL13 has the potential to be used to guide immunomodulatory therapy in MS.

Keywords: B cell; CXCL13; clinically isolated syndrome; initial clinical demyelinating event; multiple sclerosis; radiologically isolated syndrome biomarker.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

References

    1. Wekerle H. B cells in multiple sclerosis. Autoimmunity. 2017;50:57–60. doi: 10.1080/08916934.2017.1281914. - DOI - PubMed
    1. Holm Hansen R., Talbot J., Højsgaard Chow H., Bredahl Hansen M., Buhelt S., Herich S., Schwab N., Hellem M.N.N., Nielsen J.E., Sellebjerg F., et al. Increased Intrathecal Activity of Follicular Helper T Cells in Patients With Relapsing-Remitting Multiple Sclerosis. Neurol. Neuroimmunol. Neuroinflamm. 2022;9:e200009. doi: 10.1212/NXI.0000000000200009. - DOI - PMC - PubMed
    1. Thompson A.J., Banwell B.L., Barkhof F., Carroll W.M., Coetzee T., Comi G., Correale J., Fazekas F., Filippi M., Freedman M.S., et al. Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria. Lancet Neurol. 2018;17:162–173. doi: 10.1016/S1474-4422(17)30470-2. - DOI - PubMed
    1. López-Gómez J., Sacristán-Enciso B., Caro-Miró M.A., Querol Pascual M.R. Clinically isolated syndrome: Diagnosis and risk of developing clinically definite multiple sclerosis. Neurologia. 2021;21:S0213-4853. doi: 10.1016/j.nrl.2021.01.011. (In English/Spanish) - DOI - PubMed
    1. Okuda D.T., Mowry E.M., Beheshtian A., Waubant E., Baranzini S.E., Goodin D.S., Hauser S.L., Pelletier D. Incidental MRI anomalies suggestive of multiple sclerosis: The radiologically isolated syndrome. Neurology. 2009;72:800–805. doi: 10.1212/01.wnl.0000335764.14513.1a. - DOI - PubMed